NIR‐Assisted MgO‐Based Polydopamine Nanoparticles for Targeted Treatment of Parkinson's Disease through the Blood–Brain Barrier
Sign Up to like & getrecommendations! Published in 2022 at "Advanced Healthcare Materials"
DOI: 10.1002/adhm.202201655
Abstract: The blood–brain barrier (BBB) is a major limiting factor that prevents the treatment of Parkinson's disease (PD). In the present study, MgOp@PPLP nanoparticles are explored by using MgO nanoparticles as a substrate, polydopamine as a… read more here.
Keywords: mgop pplp; blood brain; brain barrier; brain ... See more keywords
Potentials and challenges of Levodopa particle formulation for treatment of Parkinson’s disease through intranasal and pulmonary delivery
Sign Up to like & getrecommendations! Published in 2020 at "Advanced Powder Technology"
DOI: 10.1016/j.apt.2020.03.028
Abstract: Abstract Inhalation drug delivery has gained interests in delivery of Levodopa for the treatment of Parkinson’s disease. In comparison to traditional oral delivery, delivery via intranasal or pulmonary pathways allows a slower drug degradation, greater… read more here.
Keywords: intranasal pulmonary; delivery; treatment parkinson; levodopa particle ... See more keywords
Discovery of VU2957 (Valiglurax): An mGlu4 Positive Allosteric Modulator Evaluated as a Preclinical Candidate for the Treatment of Parkinson's Disease.
Sign Up to like & getrecommendations! Published in 2019 at "ACS medicinal chemistry letters"
DOI: 10.1021/acsmedchemlett.8b00426
Abstract: Herein, we report the discovery of a novel potent, selective, CNS penetrant, and orally bioavailable mGlu4 PAM, VU0652957 (VU2957, Valiglurax). VU2957 possessed attractive in vitro and in vivo pharmacological and DMPK properties across species. To… read more here.
Keywords: candidate treatment; evaluated preclinical; treatment parkinson; vu2957 ... See more keywords
Intranasal Administration of Self-Oriented Nanocarriers Based on Therapeutic Exosomes for Synergistic Treatment of Parkinson's Disease.
Sign Up to like & getrecommendations! Published in 2022 at "ACS nano"
DOI: 10.1021/acsnano.1c08473
Abstract: The treatment of Parkinson's disease (PD) has been hindered by the complex pathologies and multiple membrane barriers during drug delivery. Although exosomes derived from mesenchymal stem cells (MSCs) have great potential for PD, MSC-derived exosomes… read more here.
Keywords: exo cur; parkinson disease; treatment parkinson; treatment ... See more keywords
Development of Isopropyl-Tailed Chalcones as a New Class of Selective MAO-B Inhibitors for the Treatment of Parkinson’s Disorder
Sign Up to like & getrecommendations! Published in 2023 at "ACS Omega"
DOI: 10.1021/acsomega.2c07694
Abstract: Thirteen isopropyl chalcones (CA1–CA13) were synthesized and evaluated for their inhibitory activity against monoamine oxidase (MAO). All compounds inhibited MAO-B more effectively than MAO-A. Compound CA4 most potently inhibited MAO-B with an IC50 value of… read more here.
Keywords: mao; isopropyl; ca4; treatment parkinson ... See more keywords
Opicapone for the treatment of Parkinson’s disease
Sign Up to like & getrecommendations! Published in 2017 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2017.1294683
Abstract: ABSTRACT Introduction: Parkinson’s disease (PD) is a progressive neurodegenerative disease. The currently available treatment options only have a symptomatic effect. With disease progression almost all antiparkinsonian pharmacological classes are tried, but the gold standard of… read more here.
Keywords: treatment; treatment parkinson; disease; opicapone treatment ... See more keywords
Opicapone for the treatment of Parkinson’s disease: an update
Sign Up to like & getrecommendations! Published in 2019 at "Expert Opinion on Pharmacotherapy"
DOI: 10.1080/14656566.2019.1681971
Abstract: ABSTRACT Introduction: Parkinson’s disease is a neurodegenerative disorder which is characterized by the combination of motor and non-motor symptoms. As yet, there is no curative treatment. The gold standard for symptom control is levodopa. Two… read more here.
Keywords: treatment parkinson; parkinson; opicapone treatment; parkinson disease ... See more keywords
Benefits of Vitamins in the Treatment of Parkinson's Disease
Sign Up to like & getrecommendations! Published in 2019 at "Oxidative Medicine and Cellular Longevity"
DOI: 10.1155/2019/9426867
Abstract: Parkinson's disease (PD) is the second most common neurodegenerative disease in the elderly, which is clinically characterized by bradykinesia, resting tremor, abnormal posture balance, and hypermyotonia. Currently, the pathogenic mechanism of PD remains unclear. Numerous… read more here.
Keywords: benefits vitamins; vitamins treatment; treatment; treatment parkinson ... See more keywords
Pharmaceutical Considerations of Translabial Formulations for Treatment of Parkinson's Disease: A Concept of Drug Delivery for Unconscious Patients.
Sign Up to like & getrecommendations! Published in 2022 at "Current drug delivery"
DOI: 10.2174/1567201819666220516161413
Abstract: PURPOSE The goal of the present research was to isolate a biopolymer from Phaseolus vulgaris (P. vulgaris) and Zea mays (Z. mays) plants and used it to construct Resveratrol (RES)-loaded translabial films. METHODS Biopolymers were… read more here.
Keywords: loaded translabial; translabial films; parkinson disease; res loaded ... See more keywords
Potential treatment of Parkinson's disease using new-generation carbon nanotubes: a biomolecular in silico study.
Sign Up to like & getrecommendations! Published in 2021 at "Nanomedicine"
DOI: 10.2217/nnm-2020-0372
Abstract: Background: One of the underlying mechanisms of Parkinson's disease is the aggregation of α-synuclein proteins, including amyloids and Lewy bodies in the brain. Aim: To study the inhibitory effect of doped carbon nanotubes (CNTs) on amyloid… read more here.
Keywords: potential treatment; treatment parkinson; carbon nanotubes; disease ... See more keywords
Receptor Ligands as Helping Hands to L-DOPA in the Treatment of Parkinson’s Disease
Sign Up to like & getrecommendations! Published in 2019 at "Biomolecules"
DOI: 10.3390/biom9040142
Abstract: Levodopa (LD) is the most effective drug in the treatment of Parkinson’s disease (PD). However, although it represents the “gold standard” of PD therapy, LD can cause side effects, including gastrointestinal and cardiovascular symptoms as… read more here.
Keywords: treatment; receptor ligands; treatment parkinson; parkinson disease ... See more keywords